## Blair J O'neill

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8451090/publications.pdf

Version: 2024-02-01

394421 214800 2,411 56 19 47 citations h-index g-index papers 56 56 56 2689 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Angiotensin-Converting Enzyme Inhibition With Quinapril Improves Endothelial Vasomotor Dysfunction in Patients With Coronary Artery Disease. Circulation, 1996, 94, 258-265.	1.6	864
2	Quantification of myocardial blood flow and extracellular volumes using a bolus injection of Gd-DTPA: Kinetic modeling in canine ischemic disease. Magnetic Resonance in Medicine, 1992, 23, 239-253.	3.0	180
3	Canadian Cardiovascular Society Guidelines for the Diagnosis and Management of Stable Ischemic HeartÂDisease. Canadian Journal of Cardiology, 2014, 30, 837-849.	1.7	132
4	Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: The Randomized Double-Blind Reminder Study. European Heart Journal, 2014, 35, 2295-2302.	2.2	128
5	Frequency of angiographic detection and quantitative assessment of coronary arterial disease one and three years after cardiac transplantation. American Journal of Cardiology, 1989, 63, 1221-1226.	1.6	116
6	The ketogenic diet: Pros and cons. Atherosclerosis, 2020, 292, 119-126.	0.8	113
7	Standardized Approaches to the Investigation of Syncope: Canadian Cardiovascular Society Position Paper. Canadian Journal of Cardiology, 2011, 27, 246-253.	1.7	111
8	Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Atherosclerosis, 2009, 204, 515-520.	0.8	81
9	Relative and Cumulative Effects of Lipid and Blood Pressure Control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial. Stroke, 2009, 40, 2486-2492.	2.0	66
10	Relationship of the Glu298Asp polymorphism of the endothelial nitric oxide synthase gene and early-onset coronary artery disease. American Heart Journal, 2001, 142, 586-589.	2.7	52
11	Results of operative therapy in the permanent form of junctional reciprocating tachycardia. American Journal of Cardiology, 1989, 63, 1074-1079.	1.6	46
12	Effect of low-carbohydrate diets on cardiometabolic risk, insulin resistance, and metabolic syndrome. Current Opinion in Endocrinology, Diabetes and Obesity, 2020, 27, 301-307.	2.3	45
13	The 2004 ACC/AHA Guidelines: a perspective and adaptation for Canada by the Canadian Cardiovascular Society Working Group. Canadian Journal of Cardiology, 2004, 20, 1075-9.	1.7	42
14	Treating the right patient at the right time: Access to cardiac catheterization, percutaneous coronary intervention and cardiac surgery. Canadian Journal of Cardiology, 2006, 22, 679-683.	1.7	38
15	Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment. Canadian Journal of Cardiology, 2006, 22, 511-515.	1.7	32
16	Outcomes following percutaneous coronary intervention and coronary artery bypass grafting surgery in Chinese, South Asian and white patients with acute myocardial infarction: administrative data analysis. BMC Cardiovascular Disorders, 2013, 13, 121.	1.7	31
17	Influence of smoking status on progression of endothelial dysfunction. Clinical Cardiology, 1998, 21, 331-334.	1.8	30
18	Improved prediction of early-onset coronary artery disease using APOE $\hat{l}\mu 4$ , BChE-K, PPAR $\hat{l}^3 2$ Pro12 and ENOS T-786C in a polygenic model. Clinical Biochemistry, 2006, 39, 109-114.	1.9	30

#	Article	lF	CITATIONS
19	Dietary Recommendations for Familial Hypercholesterolaemia: an Evidence-Free Zone. BMJ Evidence-Based Medicine, 2021, 26, 295-301.	3.5	21
20	Relation between butyrylcholinesterase K variant, paraoxonase 1 (PON1) Q and R and apolipoprotein E $\ddot{l}\mu 4$ genes in early-onset coronary artery disease. Clinical Biochemistry, 2002, 35, 205-209.	1.9	20
21	Strategic clinical networks in Alberta. Healthcare Management Forum, 2015, 28, 262-264.	1.4	20
22	Low carbohydrate diet: are concerns with saturated fat, lipids, and cardiovascular disease risk justified?. Current Opinion in Endocrinology, Diabetes and Obesity, 2020, 27, 291-300.	2.3	20
23	A Novel Approach to Cardiovascular Health By Optimizing Risk Management (ANCHOR): Behavioural Modification inÂPrimary Care Effectively Reduces Global Risk. Canadian Journal of Cardiology, 2013, 29, 1400-1407.	1.7	18
24	A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: A WEST sub-study. Catheterization and Cardiovascular Interventions, 2007, 70, 341-348.	1.7	16
25	Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]). American Journal of Cardiology, 2021, 148, 146-150.	1.6	15
26	A Novel Approach to Cardiovascular Health by Optimizing Risk Management (ANCHOR): A Primary Prevention Initiative Examining the Impact of Health Risk Factor Assessment and Management on Cardiac Wellness. Canadian Journal of Cardiology, 2011, 27, 809-817.	1.7	14
27	Influence of smoking status on angiotensin-converting enzyme inhibition-related improvement in coronary endothelial function. TREND Investigators. Trial on Reversing Endothelial Dysfunction. Cardiovascular Drugs and Therapy, 1999, 13, 201-209.	2.6	13
28	Aligning Health Care Policy With Evidence-Based Medicine: The Case for Funding Direct Oral Anticoagulants in Atrial Fibrillation. Canadian Journal of Cardiology, 2014, 30, 1245-1248.	1.7	11
29	Hospital variation in treatment and outcomes in acute coronary syndromes: Insights from the Alberta Contemporary Acute Coronary Syndrome Patients Invasive Treatment Strategies (COAPT) study. International Journal of Cardiology, 2017, 241, 70-75.	1.7	11
30	Universal access – but when? Treating the right patient at the right time: Access to electrophysiology services in Canada. Canadian Journal of Cardiology, 2006, 22, 741-746.	1.7	10
31	Acute coronary syndrome patients admitted to a cardiology vs non-cardiology service: variations in treatment & amp; outcome. BMC Health Services Research, 2017, 17, 354.	2.2	10
32	Applying the new STEMI guidelines: 1. Reperfusion in acute ST-segment elevation myocardial infarction. Cmaj, 2004, 171, 1039-1041.	2.0	9
33	An Integrated Approach for Vascular Health: A Call to Action. Canadian Journal of Cardiology, 2015, 31, 99-102.	1.7	9
34	The Effect of Nurse Practitioner-Led Intervention in Diabetes Care for Patients Admitted to Cardiology Services. Canadian Journal of Diabetes, 2017, 41, 10-16.	0.8	9
35	Guideline adjudicated fibrinolytic failure: Incidence, findings, and management in a contemporary clinical trial. American Heart Journal, 2008, 155, 121-127.	2.7	7
36	Canadian Cardiovascular Society Access to Care Workshop proceedings and next steps. Canadian Journal of Cardiology, 2010, 26, 69-71.	1.7	6

#	Article	lF	CITATIONS
37	Comparison of fixed-wire and over-the-wire balloon dilatation systems for percutaneous transluminal coronary angioplasty. American Journal of Cardiology, 1994, 73, 113-116.	1.6	5
38	Does the speed of balloon deflation affect the complication rate of coronary angioplasty?. American Journal of Cardiology, 1994, 73, 228-230.	1.6	4
39	Anticoagulation after subcutaneous enoxaparin is time sensitive in STEMI patients treated with tenecteplase. Journal of Thrombosis and Thrombolysis, 2012, 34, 126-131.	2.1	4
40	How do hospital administrators perceive cardiac rehabilitation in a publicly-funded health care system?. BMC Health Services Research, 2013, 13, 120.	2.2	4
41	Improved Wait Times for Coronary Revascularization: Cause to Celebrate Spotting the Iceberg in Time or Time to Look Under the Surface?. Canadian Journal of Cardiology, 2011, 27, 263.e1-263.e3.	1.7	3
42	Survey of Diabetes Care in Patients Presenting With Acute Coronary Syndromes in Canada. Canadian Journal of Cardiology, 2013, 29, 1134-1137.	1.7	3
43	Spindle Cell Sarcoma of the Left Atrium: An Extremely Rare and Challenging Tumour Often Masquerading as Left Atrial Myxoma. Canadian Journal of Cardiology, 2015, 31, 104.e5-104.e6.	1.7	3
44	Quality of Cardiac Care in Canada: Recommendations for Building a Sustainable Future. Canadian Journal of Cardiology, 2018, 34, 800-803.	1.7	3
45	Strategic Clinical Networks: Alberta's Response to Triple Aim. HealthcarePapers, 2016, 15, 49-54.	0.3	3
46	Revascularization Strategies for Coronary Disease: Art or Science?. Canadian Journal of Cardiology, 2014, 30, 1153-1154.	1.7	2
47	The politicization of the wait times issue – and how to rise above it. Canadian Journal of Cardiology, 2008, 24, 113.	1.7	1
48	Treatment of a coronary artery to superior vena cava fistula resulting from early closure of a Possis Perma-Flow graft. Catheterization and Cardiovascular Interventions, 1999, 47, 191-193.	1.7	0
49	Applying the new STEMI guidelines: 2. Disturbances of cardiac rhythm after ST-segment elevation myocardial infarction. Cmaj, 2004, 171, 1042-1044.	2.0	0
50	Enoxaprin may be more effective than unfractionated heparin for people with high-risk non ST-segment elevation acute coronary syndromes. Evidence-based Cardiovascular Medicine, 2006, 10, 113-115.	0.0	0
51	Medical wait lists. Cmaj, 2006, 174, 1598-1599.	2.0	0
52	Birnbaum LM, Filion KB, Joyal D, Eisenberg MJ. Second reading of coronary angiograms by radiologists. Can J Cardiol 2006;22(14):1217-1221. Canadian Journal of Cardiology, 2007, 23, 864-924.	1.7	0
53	The Canadian Cardiovascular Society thanks Pulsus Group. Canadian Journal of Cardiology, 2010, 26, 516.	1.7	0
54	Timely Access to Acute Cardiac Care: Can It Overcome a Lifetime of Despair?. Canadian Journal of Cardiology, 2012, 28, 155-157.	1.7	0

## BLAIR J O'NEILL

#	Article	IF	CITATIONS
55	Simple Laboratory Test-Based Risk Scores in Coronary Catheterization: Development, Validation, and Comparison to Conventional Risk Factors. journal of applied laboratory medicine, The, 2020, 5, 616-630.	1.3	O
56	A case of electrical right ventricular infarction in the absence of clinical right ventricular failure. CJC Open, 2021, 4, 340-343.	1.5	0